Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,003 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo (0.9% NaCl) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function

NCT00949663
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25, Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 3 Interventional

Herniorrhaphy for Postoperative Pain

NCT05813847
View directory record Official record
Conditions
Hernia, Inguinal, Post Operative Pain
Interventions
local anaesthetic injection of CPL-01, Morphine (rescue medication), Acetaminophen (rescue medication), Oxycodone (rescue medication), local anaesthetic injection of placebo, local anaesthetic injection of ropivacaine HCl, Open inguinal hernia repair
Drug · Procedure
Lead sponsor
Cali Pharmaceuticals LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Terminated Phase 2 Interventional

Single Dose Enteral Tranexamic Acid in Critically Ill Patients

NCT01683747
View directory record Official record
Conditions
Shock, Sepsis, Hypotension, Critical Illness
Interventions
Tranexamic Acid, Control Intervention (Carrier fluid only)
Drug
Lead sponsor
San Diego Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 29, 2026, 1:27 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Use of Pre-Emptive Pudendal Nerve Block for Pelvic Reconstructive Surgery

NCT02409498
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
pudendal block, no pudendal block
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 1 Interventional

Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis

NCT03542838
View directory record Official record
Conditions
Osteoarthritis, Knee, Pain, Knee
Interventions
Resiniferatoxin, Saline
Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
35 Years to 85 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

Safety, Efficacy and Treatment Regimen Study of ST266 in Subjects With Moderate to Severe Periodontitis

NCT02761993
View directory record Official record
Conditions
Periodontal Disease
Interventions
ST266, Saline (0.9% NaCl)
Biological · Drug
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years to 85 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Cambridge, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 4 Interventional Results available

Dexamethasone for Post Cesarean Delivery Analgesia

NCT01868633
View directory record Official record
Conditions
Postoperative Pain
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Metoclopramide for Post Traumatic Headache

NCT03220958
View directory record Official record
Conditions
Post-Traumatic Headache
Interventions
Metoclopramide, Diphenhydramine, Normal saline
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 4 Interventional Results available

Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine

NCT02403830
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Methylnaltrexone, Placebo, Morphine, Ticagrelor
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis

NCT02493257
View directory record Official record
Conditions
Nonallergic Irritant Rhinitis
Interventions
Capsaicin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of TT301 on Cytokine Levels Post Endotoxin Challenge

NCT01357421
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
TT301, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Sep 29, 2026, 1:27 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer

NCT01038752
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Suramin Drug:Docetaxel Drug: Carboplatin, Placebo Drug: Docetaxel Drug: Carboplatin
Drug
Lead sponsor
Optimum Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Chicago, Illinois • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 4 Interventional Results available

Effect of Dexmedetomidine on Emergence Agitation in Children With or Without Tube Insertion Under General Anesthesia

NCT01535287
View directory record Official record
Conditions
Myringotomy
Interventions
Dexmedetomidine
Drug
Lead sponsor
Martin Mueller
Other
Eligibility
1 Year to 10 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection

NCT03099863
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Cystoscopic Fluid containing Neosporin G. U. Irrigant, Cystoscopy, Cystoscopic Fluid/Placebo
Drug · Procedure
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of Monovisc® Injection for Osteoarthritis of the Knee

NCT00653432
View directory record Official record
Conditions
Osteoarthritis
Interventions
Monovisc®, Saline
Device · Other
Lead sponsor
Anika Therapeutics, Inc.
Industry
Eligibility
35 Years to 75 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
30
States / cities
Hoover, Alabama • Mesa, Arizona • Phoenix, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 1 Interventional

A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face

NCT05784363
View directory record Official record
Conditions
Enlarged Pores, Sebum Production
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
21 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Coral Gables, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 29, 2026, 1:27 AM EDT
Recruiting Phase 2 Interventional

Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone

NCT04049331
View directory record Official record
Conditions
Hypogonadism, Male, Fatigue Syndrome, Chronic
Interventions
Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED], placebo
Drug · Other
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 54 Years · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Terminated Phase 3 Interventional

Effect of IV Vitamin C, Thiamine, and Steroids on Mortality of Septic Shock

NCT03828929
View directory record Official record
Conditions
Septic Shock
Interventions
Vitamin C, Normal saline
Drug
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2020 · Synced Sep 29, 2026, 1:27 AM EDT
Withdrawn Not applicable Interventional

Effect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial Cystitis

NCT00823030
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
Urodynamic study, Lidocaine, Normal Saline
Procedure · Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults

NCT04661839
View directory record Official record
Conditions
COVID-19
Interventions
COVID-HIGIV, Placebo (saline)
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI

NCT03829475
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Clostridium Difficile Infection
Interventions
Bezlotoxumab, Placebo, Fecal Microbiota Transplantation
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 4 Interventional Results available

Dexmedetomidine and IV Acetaminophen for the Prevention of Postoperative Delirium Following Cardiac Surgery

NCT02546765
View directory record Official record
Conditions
Delirium
Interventions
IV acetaminophen & IV propofol, IV acetaminophen & IV dexmedetomidine, IV propofol & placebo, IV dexmedetomidine & placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
60 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 2 Interventional

CER-001 Atherosclerosis Regression ACS Trial

NCT02484378
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
CER-001, Placebo
Drug
Lead sponsor
Cerenis Therapeutics, SA
Industry
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Huntsville, Alabama • San Diego, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2019 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 4 Interventional

Oral vs IV Sedation for Cataract Surgery in Older Adults

NCT07154147
View directory record Official record
Conditions
Cataract Surgery, Sedation, Cognition Function, Perioperative Care, Older Adults
Interventions
Alprazolam, Midazolam
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 29, 2026, 1:27 AM EDT